Price Gouging and the Dangerous New Breed of Pharma Companies
Harvard Business Review
JULY 6, 2016
I met Tony in 2001 when he was sent to me with severe muscle weakness. Confined to a wheelchair and unable to care for himself, Tony had been told he had amyotrophic lateral sclerosis, or ALS, a fatal neurodegenerative disorder. It turned out Tony actually had Lambert-Eaton myasthenic syndrome, a rare but treatable neuromuscular disorder. After starting the drug 3,4 diaminopyridine (3,4 DAP), he regained most of his strength and, significantly, his ability to walk and care for himself.
Let's personalize your content